During spring 2021, AZD1222 and BNT162b2 were used as prime and BNT162b2 as
booster COVID-19 vaccines in Denmark. We obtained self-reported information on systemic …

Background This study evaluates the immunogenicity and reactogenicity of BNT162b2 and
mRNA-1273 booster doses after the primary two-dose BNT162b2 series in Japan and is the …

At the start of the SARS-CoV-2 pandemic, healthcare workers had an increased risk of
acquiring coronavirus disease (COVID)-19. As tertiary care hospitals are critical for the …

Background Since the beginning of the COVID-19 vaccination campaigns,
recommendations regarding the vaccination have been very dynamic. Although the safety …

Background Current recommendations in the United States are that subjects with a previous
history of COVID-19 disease receive the full 2 dose mRNA vaccine regimen. We tested the …

Background The aim of our study was to assess the impact the impact of gender and age on
reactogenicity to three COVID-19 vaccine products: Biontech/Pfizer (BNT162b2), Moderna …

In a previous study, we described a highly significant association between reactogenicity
and SARS-CoV-2 RBD IgG titers and wild-type neutralization capacity in males after basic …

Objectives A weak correlation between symptom severity and antibody levels after primary
immunization against COVID-19 has already been shown. This study aimed to describe the …

Introduction: The BNT162b2 vaccination studies did not specifically focus on groups that
were heavily exposed to SARS-CoV-2 infection. Therefore, we aimed to assess the safety …

Background Studies correlating reactogenicity and immunogenicity of COVID-19 vaccines
are limited to BNT162b2, with inconsistent results. We investigated whether adverse …